Cryoport（CKX）株式概要Cryoport, Inc.は、世界中のバイオ医薬品/製薬、動物医療、生殖医療市場において、温度制御サプライチェーンソリューションを提供しています。 詳細CKX ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績0/6財務の健全性4/6配当金0/6報酬収益は年間9.21%増加すると予測されています 過去5年間の収益は年間19.9%増加しました。 リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない German市場と比較した過去 3 か月間の株価の変動過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見るCKX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€12.0019.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-293m284m2016201920222025202620282031Revenue US$284.1mEarnings US$36.3mAdvancedSet Fair ValueView all narrativesCryoport, Inc. 競合他社EvotecSymbol: XTRA:EVTMarket cap: €929.6mGerresheimerSymbol: XTRA:GXIMarket cap: €943.6mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €2.6bSartoriusSymbol: XTRA:SRT3Market cap: €14.5b価格と性能株価の高値、安値、推移の概要Cryoport過去の株価現在の株価US$12.0052週高値US$12.4052週安値US$4.50ベータ1.751ヶ月の変化41.18%3ヶ月変化73.91%1年変化133.01%3年間の変化-31.43%5年間の変化n/aIPOからの変化-51.98%最新ニュースBuy Or Sell Opportunity • May 21Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to €11.90. The fair value is estimated to be €9.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 06Cryoport, Inc. Raises Revenue Guidance for the Full-Year 2026Cryoport, Inc. raised revenue guidance for the full-year 2026. For the year, the company raised revenue guidance to $192 million to $196 million.お知らせ • Apr 23Cryoport, Inc., Annual General Meeting, Jun 05, 2026Cryoport, Inc., Annual General Meeting, Jun 05, 2026.お知らせ • Apr 21Cryoport, Inc. to Report Q1, 2026 Results on May 04, 2026Cryoport, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026お知らせ • Mar 04Cryoport, Inc. Provides Revenue Guidance for the Full-Year 2026Cryoport, Inc. provided revenue guidance for the full-year 2026. The Company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.最新情報をもっと見るRecent updatesBuy Or Sell Opportunity • May 21Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to €11.90. The fair value is estimated to be €9.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 06Cryoport, Inc. Raises Revenue Guidance for the Full-Year 2026Cryoport, Inc. raised revenue guidance for the full-year 2026. For the year, the company raised revenue guidance to $192 million to $196 million.お知らせ • Apr 23Cryoport, Inc., Annual General Meeting, Jun 05, 2026Cryoport, Inc., Annual General Meeting, Jun 05, 2026.お知らせ • Apr 21Cryoport, Inc. to Report Q1, 2026 Results on May 04, 2026Cryoport, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026お知らせ • Mar 04Cryoport, Inc. Provides Revenue Guidance for the Full-Year 2026Cryoport, Inc. provided revenue guidance for the full-year 2026. The Company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.お知らせ • Feb 17Cryoport, Inc. to Report Q4, 2025 Results on Mar 03, 2026Cryoport, Inc. announced that they will report Q4, 2025 results at 4:05 PM, US Eastern Standard Time on Mar 03, 2026お知らせ • Feb 11Cryoport's MVE Biological Solutions Introduces New Fusion 800 SeriesCryoport, Inc. announced the launch of the MVE Fusion 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN2) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments. Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted erformance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly acility modifications. Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C.お知らせ • Nov 05Cryoport, Inc. Updates Revenue Guidance for the Fiscal Year 2025Cryoport, Inc. updated revenue guidance for the fiscal year 2025. With momentum and year-to-date performance along with strong Third Quarter results, the company raising full-year revenue guidance from continuing operations to a range of $170.0 million to $174.0 million.お知らせ • Oct 21Cryoport, Inc. to Report Q3, 2025 Results on Nov 04, 2025Cryoport, Inc. announced that they will report Q3, 2025 results at 4:05 PM, US Eastern Standard Time on Nov 04, 2025お知らせ • Oct 07Cryoport, Inc. Introduces Real-Time Integrated Condition Monitoring Systems for Cryogenic DewarsCryoport, Inc. announced the unveiling of MVE Biological Solutions integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company. This launch reflects MVE's commitment to support the life sciences with intelligent, connected assets to safeguard vital commodities. Combining MVE's trusted cryogenic systems with advanced condition monitoring technology, the new monitoring and visibility systems integrate either a SmartTagTM or CryoBeaconTM, built directly into dewar lids, to provide centralized condition monitoring. All collected data is managed within the MVECloudTM, a secure web- and mobile-based FDA 21 CFR Part 11, GAMP 5 compliant platform that provides visibility, real time alerts, and reporting on the cryogenic environment in which commodities are stored. The CryoBeacon is a long-range Bluetooth Low Energy (BLE) 5.0 device that logs internal temperatures as low as -200degC, along with ambient temperature and humidity. Users can instantly retrieve data by scanning a QR code, making it easy to monitor both shipments and stationary storage equipment. The MVE SmartTag is a real-time condition-monitoring device with Long Term Evolution (LTE) connectivity and up to 120 days of battery life. It provides continuous visibility and alerts during transport or storage.お知らせ • Aug 13Cryoport, Inc. announced delayed 10-Q filingOn 08/12/2025, Cryoport, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. For the period, the company is reiterating its revenue guidance for fiscal year 2025: total revenue from continuing operations is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of the control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.お知らせ • Jul 22Cryoport, Inc. to Report Q2, 2025 Results on Aug 05, 2025Cryoport, Inc. announced that they will report Q2, 2025 results at 4:05 PM, US Eastern Standard Time on Aug 05, 2025お知らせ • Jul 08Cryoport's Mve Biological Solutions Introduces Next Generation Vapor ShippersCryoport, Inc. announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures. Built on MVE's legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments. These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissues materials for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines, while maintaining the materials' integrity throughout the journey. The new SC 4/2V andSC 4/3V vapor shippers include several key advancements designed to enhance performance and reliability. Hold times for both next-generation models have been significantly extended to up to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days) which provides greater flexibility and security during transit delays. MVE's patented BEND DON'T BREAK™? technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping. Other upgraded features of the new vapor shippers include a newly integrated lid locking tab which helps prevent breakage, along with MVE's patent-pending Vapor Shield Technology, which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling. These enhancements work together to provide greater reliability and " peace of mind" when transporting critical biological materials.お知らせ • May 08Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. The company is reiterating its revenue guidance for fiscal year 2025: total organic revenue is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.お知らせ • Apr 28Cryoport, Inc., Annual General Meeting, Jun 06, 2025Cryoport, Inc., Annual General Meeting, Jun 06, 2025.お知らせ • Apr 24Cryoport, Inc. to Report Q1, 2025 Results on May 07, 2025Cryoport, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025お知らせ • Apr 02DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX).DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX) on March 31, 2025. In a related party transaction DHL Supply Chain International Holding B.V. also agreed to acquire Courier Polar Expres S.L., Advanced Therapy Logistics and Solutions, SAS and Cryo Express GmbH. for approximately $138 million in cash. The Transaction is expected to close in the second or third quarter of 2025 and is subject to customary closing conditions, including regulatory approval under relevant government antitrust and foreign direct investment laws.お知らせ • Mar 12Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series with Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical LaboratoriesCryoport, Inc. announced the launch of MVE Biological Solutions' High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories. Building on the trusted reputation of the HE Series, the HE 800 C provides ultra-low temperature storage at -190degC, ensuring the integrity of sensitive biological materials. The HE 800 C is compatible with SUC-1 inventory management systems, which enables easy identification and retrieval of samples to streamline sample organization and retrieval. Its superior ergonomic design makes loading and retrieving samples more accessible, reducing strain on laboratory personnel.お知らせ • Mar 05Cryoport, Inc. Provides Revenue Guidance for the Year 2025Cryoport, Inc. provided revenue guidance for the year 2025. For the year, the company expects revenue guidance in the range of $240 million - $250 million. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.お知らせ • Feb 18Cryoport, Inc. to Report Q4, 2024 Results on Mar 04, 2025Cryoport, Inc. announced that they will report Q4, 2024 results at 4:05 PM, US Eastern Standard Time on Mar 04, 2025お知らせ • Jan 22Cryoport, Inc. Unveils Cryoport Express Cryogenic HV3 Shipping SystemCryoport, Inc. unveiled its Cryoport Express Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings. The HV3 ensures unparalleled protection and accessibility for biologics and other temperature-sensitive materials. Its unique rectilinear design eliminates the need for palletization (securing goods on a pallet for transportation) and provides the ability to transport critical life science materials on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. As a result, the HV3 increases the number of available shipping lanes, which will improve patient access and enable life-saving therapies to reach patients in underserved areas. This newly developed shipping system offers enhanced payload protection and resilience during transport. With additional space for non-temperature sensitive accessories and documentation, the HV3 also improves storage efficiency through the ability to stack and nest the shippers, making it more cost-effective and user-friendly. Full compliance with airline requirements plus an integrated condition and location monitoring system provides full Chain of Compliance. Engineered to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security and superior temperature control, maintaining payload integrity and extended temperature stability at -150degC or lower. The HV3's structure also enhances mobility with its robust wheels and an integrated front-facing handle, improving accessibility at point-of-care sites. Its design also provides for scalability or higher density storage capabilities at manufacturing and clinical sites. While improving overall safety for clinicians and operators, these improvements enable more efficient handling (and storage) at point-of-care site, contract development and manufacturing organizations (CDMO's), and other storage locations, reducing the need for additional site-based resources. The HV3 is also designed to be used with Cryoport's Safepak System. The Safepak System is a purpose built solution that utilizes non-metallic, soft materials to minimize the effects of vibration and shock during the transport of cell and gene therapies.Reported Earnings • Nov 09Third quarter 2024 earnings released: EPS: US$0.057 (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.057 (up from US$0.31 loss in 3Q 2023). Revenue: US$56.7m (flat on 3Q 2023). Net income: US$2.81m (up US$18.1m from 3Q 2023). Profit margin: 5.0% (up from net loss in 3Q 2023). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.Reported Earnings • Aug 07Second quarter 2024 earnings released: US$1.62 loss per share (vs US$0.42 loss in 2Q 2023)Second quarter 2024 results: US$1.62 loss per share (further deteriorated from US$0.42 loss in 2Q 2023). Revenue: US$57.6m (up 1.0% from 2Q 2023). Net loss: US$80.0m (loss widened 293% from 2Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Aug 07+ 1 more updateCryoport, Inc. (NasdaqCM:CYRX) announces an Equity Buyback for $200 million worth of its shares.Cryoport, Inc. (NasdaqCM:CYRX) announces an share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The repurchase program is valid till December 31, 2027.お知らせ • Jul 23Cryoport, Inc. to Report Q2, 2024 Results on Aug 06, 2024Cryoport, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024Recent Insider Transactions • May 17Independent Lead Director recently sold €100k worth of stockOn the 15th of May, Richard Jay Berman sold around 8k shares on-market at roughly €12.34 per share. This transaction amounted to 7.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €271k more than they bought in the last 12 months.Reported Earnings • May 08First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.16 loss in 1Q 2023)First quarter 2024 results: US$0.34 loss per share (further deteriorated from US$0.16 loss in 1Q 2023). Revenue: US$54.6m (down 13% from 1Q 2023). Net loss: US$16.9m (loss widened 123% from 1Q 2023). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • May 08Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024Cryoport, Inc. reiterated revenue guidance for the full year 2024. The Company is reiterating its full year 2024 revenue guidance of $242 million to $252 million and continues to expect revenue to improve progressively throughout the year.New Risk • May 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$48m net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (7.9% increase in shares outstanding).お知らせ • May 01Cryoport, Inc. to Report Q1, 2024 Results on May 07, 2024Cryoport, Inc. announced that they will report Q1, 2024 results at 4:05 PM, US Eastern Standard Time on May 07, 2024お知らせ • Apr 04Cryoport, Inc., Annual General Meeting, May 17, 2024Cryoport, Inc., Annual General Meeting, May 17, 2024, at 10:00 Central Daylight. Agenda: To elect seven directors; to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company and its subsidiaries for the year ending December 31, 2024; to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in proxy statement for the Annual Meeting; to approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares under the plan; and to transact such other business as may properly come before the meeting or any adjournment thereof.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 14Cryoport, Inc. Announces Goodwill Impairment for the Quarter Ended December 31, 2023Cryoport, Inc. announced goodwill impairment for the quarter ended December 31, 2023. For the quarter, the company reported Goodwill impairment of $49,569,000.お知らせ • Mar 13Cryoport, Inc. Provides Revenue Guidance for the Year 2024Cryoport, Inc. provided revenue guidance for the year 2024. The Company is expecting revenue to grow progressively and is providing full year 2024 revenue guidance of $242 million- $252 million.Reported Earnings • Mar 13Full year 2023 earnings released: US$2.21 loss per share (vs US$0.93 loss in FY 2022)Full year 2023 results: US$2.21 loss per share (further deteriorated from US$0.93 loss in FY 2022). Revenue: US$233.3m (down 1.7% from FY 2022). Net loss: US$107.6m (loss widened 137% from FY 2022). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 28Cryoport, Inc. to Report Q4, 2023 Results on Mar 12, 2024Cryoport, Inc. announced that they will report Q4, 2023 results After-Market on Mar 12, 2024お知らせ • Feb 16Cryoport, Inc. Announces Transition of Edward Zecchini from the Board of Directors to Sr. Vice President - Chief Digital & Technology OfficerOn February 10, 2024, Edward Zecchini accepted the offer to join Cryoport, Inc. as Senior Vice President – Chief Digital & Technology Officer and submitted his resignation from the Board of Directors of the Company both effective February 19, 2024. There were no disagreements between Mr. Zecchini and the Company on any matter relating to the Company’s operations, policies or practices that led to his decision to resign.New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$47m net loss in 2 years).お知らせ • Nov 17Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC.Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC on November 16, 2023. Bluebird Express team of seasoned veterans will merge into CRYOPDP's global network and will expand U.S. presence.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Bluebird Express LLC on November 16, 2023.お知らせ • Nov 10Cryoport, Inc. Provides Revenue Guidance for the Year 2023Cryoport, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 revenue guidance range of $233 million to $243 million.Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.15 loss in 3Q 2022)Third quarter 2023 results: US$0.31 loss per share (further deteriorated from US$0.15 loss in 3Q 2022). Revenue: US$56.2m (down 7.1% from 3Q 2022). Net loss: US$15.3m (loss widened 109% from 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 03Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH.Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH on November 2, 2023.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Tec4Med Lifescience GmbH on November 2, 2023.お知らせ • Oct 26Cryoport, Inc. to Report Q3, 2023 Results on Nov 08, 2023Cryoport, Inc. announced that they will report Q3, 2023 results at 4:05 PM, US Eastern Standard Time on Nov 08, 2023Reported Earnings • Aug 10Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.23 loss in 2Q 2022)Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.23 loss in 2Q 2022). Revenue: US$57.0m (down 11% from 2Q 2022). Net loss: US$20.4m (loss widened 82% from 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Aug 03Cryoport, Inc. to Report Q2, 2023 Results on Aug 09, 2023Cryoport, Inc. announced that they will report Q2, 2023 results at 4:05 PM, US Eastern Standard Time on Aug 09, 2023New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Significant insider selling over the past 3 months (€142k sold).お知らせ • Jul 13Cryoport, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023Cryoport, Inc. provided earnings guidance for the second quarter and full year 2023. For the quarter, total revenue is expected to be in the range of $56.5 Million to $57.5 Million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022. For the year, the Company is revising its full year financial outlook, with revenue now expected to be in the range of $233 Million to $243 Million.Recent Insider Transactions • May 15Independent Lead Director recently sold €142k worth of stockOn the 11th of May, Richard Jay Berman sold around 7k shares on-market at roughly €19.70 per share. This transaction amounted to 6.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €575k more than they bought in the last 12 months.Reported Earnings • May 05First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.31 loss in 1Q 2022)First quarter 2023 results: US$0.16 loss per share (improved from US$0.31 loss in 1Q 2022). Revenue: US$62.8m (up 20% from 1Q 2022). Net loss: US$7.57m (loss narrowed 51% from 1Q 2022).お知らせ • May 05Cryoport, Inc. Provides Revenue Guidance for the Year 2023Cryoport, Inc. provided revenue guidance for the year 2023. The company's revenue guidance of $270 million - $290 million for the full year 2023 is expected to be driven largely by ongoing support of global clinical trials, a growing number of commercial cell and gene therapy products from clients, the expansion of cell and gene manufacturing capacity to meet patient demand, and the demand for biostorage and cryogenic freezer systems. The company's 2023 guidance also assumes the launch of new services and products, designed to further expand, and strengthen industry position.Recent Insider Transactions • Mar 19Chairman recently sold €51k worth of stockOn the 15th of March, Jerrell Shelton sold around 3k shares on-market at roughly €19.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jerrell's only on-market trade for the last 12 months.Breakeven Date Change • Feb 26No longer forecast to breakevenThe 9 analysts covering Cryoport no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.70m in 2025. New consensus forecast suggests the company will make a loss of US$2.40m in 2025.お知らせ • Feb 16Cryoport, Inc. to Report Q4, 2022 Results on Feb 23, 2023Cryoport, Inc. announced that they will report Q4, 2022 results at 4:05 PM, US Eastern Standard Time on Feb 23, 2023Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$7.70m in 2025. Average annual earnings growth of 40% is required to achieve expected profit on schedule.Recent Insider Transactions • Dec 06Independent Lead Director recently sold €136k worth of stockOn the 1st of December, Richard Jay Berman sold around 7k shares on-market at roughly €18.70 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €334k more than they bought in the last 12 months.Reported Earnings • Nov 05Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2021)Third quarter 2022 results: US$0.15 loss per share (improved from US$0.18 loss in 3Q 2021). Revenue: US$60.5m (up 6.7% from 3Q 2021). Net loss: US$7.32m (loss narrowed 14% from 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 04Cryoport, Inc. Revises Revenue Guidance for the Year 2022Cryoport, Inc. revised revenue guidance for the year 2022. The company's revised revenue guidance for the full year 2022 is $232 million - $238 million, and will be driven primarily by the growth from support of global clinical trials and commercially launched therapies from cell and gene therapy clients; growth in temperature-controlled logistics for the life sciences industry; and demand for cryogenic systems solutions.お知らせ • Oct 28Cryoport, Inc. to Report Q3, 2022 Results on Nov 03, 2022Cryoport, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2022Recent Insider Transactions • Aug 18Independent Lead Director recently sold €115k worth of stockOn the 16th of August, Richard Jay Berman sold around 3k shares on-market at roughly €42.31 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €198k more than they bought in the last 12 months.Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.16 loss in 2Q 2021)Second quarter 2022 results: US$0.15 loss per share (up from US$0.16 loss in 2Q 2021). Revenue: US$64.2m (up 14% from 2Q 2021). Net loss: US$7.18m (loss narrowed 2.9% from 2Q 2021). Over the next year, revenue is forecast to grow 21%, compared to a 7.2% growth forecast for the industry in Germany.お知らせ • Aug 05+ 1 more updateCryoport, Inc. (NasdaqCM:CYRX) acquired Cell Matters Sa.Cryoport, Inc. (NasdaqCM:CYRX) acquired Cell Matters Sa on August 4, 2022. Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Cell Matters Sa on August 4, 2022.お知らせ • Jul 29Cryoport, Inc. to Report Q2, 2022 Results on Aug 04, 2022Cryoport, Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022Breakeven Date Change • Jun 13Forecast to breakeven in 2024The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 84% per year to 2023. The company is expected to make a profit of US$5.75m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.株主還元CKXDE Life SciencesDE 市場7D8.1%11.9%3.2%1Y133.0%-10.8%2.5%株主還元を見る業界別リターン: CKX過去 1 年間で-10.8 % の収益を上げたGerman Life Sciences業界を上回りました。リターン対市場: CKX過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is CKX's price volatile compared to industry and market?CKX volatilityCKX Average Weekly Movement9.2%Life Sciences Industry Average Movement9.0%Market Average Movement6.1%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.7%安定した株価: CKXの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CKXの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1999688Jerry Sheltonwww.cryoportinc.comCryoport, Inc.は、世界中のバイオ医薬品／製薬、動物医療、生殖医療市場において、温度管理されたサプライチェーン・ソリューションを提供している。ライフサイエンスサービス事業では、ライフサイエンス業界向けに温度制御ロジスティクスと極低温バイオストレージを提供している。ライフサイエンス製品部門は、ライフサイエンス業界向けに極低温フリーザー、極低温デュワー、アクセサリーを直販または流通ネットワークを通じて提供している。同社の製品には、Cryoport Express Shippers、Cryoport ELITE Shippers、Cryoport Express Cryogenic HV3 Shipping System、Smartpak II Condition Monitoring System、Tec4Med、Cryoportアクセサリーがある。また、Cryoport BioStorage/Bioservicesとして、前臨床の温度管理された生物学的材料管理サービスを提供するための生物学的保管ソリューションCRYOGENEや、温度管理された保管、キッティング、ラベリング、フルフィルメント、サンプル管理、医薬品返却、Qualified Person医薬品リリースを含むCryoport Systems Bioservicesを提供している。さらに、アフェレシス/ロイカフェレシス採取、クライオシャトル輸送、クライオプロセス最適化、凍結保存サービスからなるIntegriCellサービス、輸送システムおよび/または包装の物理的、熱的、輸送適格性評価からカスタム包装ソリューションの開発までを含むCryoportコンサルティングサービス、温度制御ロジスティクスソリューションであるCRYOPDP、自立型クライオフリーザーであるMVE Biological SolutionsのFusionクライオジェニックシステム、クライオジェニックフリーザーシステムであるVarioクライオジェニックシステムを提供している。さらに、生物試料の凍結保存とメンテナンス、試料のアーカイブ、モニタリング、追跡、受領、配送、凍結生物試料の輸送、生物試料の入出庫管理、短期ロジスティクスとエンジニアリング・コンサルティング・サービスも提供している。同社は1999年に設立され、テネシー州ブレントウッドを拠点としている。もっと見るCryoport, Inc. 基礎のまとめCryoport の収益と売上を時価総額と比較するとどうか。CKX 基礎統計学時価総額€607.97m収益（TTM）-€38.48m売上高(TTM)€157.62m3.9xP/Sレシオ-15.8xPER（株価収益率CKX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CKX 損益計算書（TTM）収益US$182.94m売上原価US$96.61m売上総利益US$86.33mその他の費用US$130.99m収益-US$44.66m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.89グロス・マージン47.19%純利益率-24.41%有利子負債／自己資本比率37.7%CKX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 07:25終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cryoport, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Paul KnightBrean Capital Historical (Janney Montgomery)Andrew D'SilvaB. Riley Securities, Inc.Yuan ZhiB. Riley Securities, Inc.11 その他のアナリストを表示
Buy Or Sell Opportunity • May 21Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to €11.90. The fair value is estimated to be €9.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 06Cryoport, Inc. Raises Revenue Guidance for the Full-Year 2026Cryoport, Inc. raised revenue guidance for the full-year 2026. For the year, the company raised revenue guidance to $192 million to $196 million.
お知らせ • Apr 23Cryoport, Inc., Annual General Meeting, Jun 05, 2026Cryoport, Inc., Annual General Meeting, Jun 05, 2026.
お知らせ • Apr 21Cryoport, Inc. to Report Q1, 2026 Results on May 04, 2026Cryoport, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026
お知らせ • Mar 04Cryoport, Inc. Provides Revenue Guidance for the Full-Year 2026Cryoport, Inc. provided revenue guidance for the full-year 2026. The Company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
Buy Or Sell Opportunity • May 21Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 65% to €11.90. The fair value is estimated to be €9.33, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 7.6%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings are also forecast to grow by 14% per annum over the same time period.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 6 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 06Cryoport, Inc. Raises Revenue Guidance for the Full-Year 2026Cryoport, Inc. raised revenue guidance for the full-year 2026. For the year, the company raised revenue guidance to $192 million to $196 million.
お知らせ • Apr 23Cryoport, Inc., Annual General Meeting, Jun 05, 2026Cryoport, Inc., Annual General Meeting, Jun 05, 2026.
お知らせ • Apr 21Cryoport, Inc. to Report Q1, 2026 Results on May 04, 2026Cryoport, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026
お知らせ • Mar 04Cryoport, Inc. Provides Revenue Guidance for the Full-Year 2026Cryoport, Inc. provided revenue guidance for the full-year 2026. The Company provided full-year 2026 revenue guidance in the range of $190.0 million to $194.0 million. The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, any U.S. federal government shutdown, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
お知らせ • Feb 17Cryoport, Inc. to Report Q4, 2025 Results on Mar 03, 2026Cryoport, Inc. announced that they will report Q4, 2025 results at 4:05 PM, US Eastern Standard Time on Mar 03, 2026
お知らせ • Feb 11Cryoport's MVE Biological Solutions Introduces New Fusion 800 SeriesCryoport, Inc. announced the launch of the MVE Fusion 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN2) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments. Recognized with the ISBER Outstanding New Product Award, MVE's Fusion technology transforms cryogenic storage. The new Fusion 800 builds on this innovative platform, offering the same trusted erformance and energy efficiency in a lab-sized design. At just 32 inches wide, it fits through standard doorways for easy installation without costly acility modifications. Ideal for medical research facilities, clinical development operations, hospital pharmacies and clinics, biorepositories, and blood and tissue banks, etc., the Fusion 800 offers versatile storage options for vials, blood bags, cassettes, etc., maintaining steady state temperatures at or below -150°C.
お知らせ • Nov 05Cryoport, Inc. Updates Revenue Guidance for the Fiscal Year 2025Cryoport, Inc. updated revenue guidance for the fiscal year 2025. With momentum and year-to-date performance along with strong Third Quarter results, the company raising full-year revenue guidance from continuing operations to a range of $170.0 million to $174.0 million.
お知らせ • Oct 21Cryoport, Inc. to Report Q3, 2025 Results on Nov 04, 2025Cryoport, Inc. announced that they will report Q3, 2025 results at 4:05 PM, US Eastern Standard Time on Nov 04, 2025
お知らせ • Oct 07Cryoport, Inc. Introduces Real-Time Integrated Condition Monitoring Systems for Cryogenic DewarsCryoport, Inc. announced the unveiling of MVE Biological Solutions integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company. This launch reflects MVE's commitment to support the life sciences with intelligent, connected assets to safeguard vital commodities. Combining MVE's trusted cryogenic systems with advanced condition monitoring technology, the new monitoring and visibility systems integrate either a SmartTagTM or CryoBeaconTM, built directly into dewar lids, to provide centralized condition monitoring. All collected data is managed within the MVECloudTM, a secure web- and mobile-based FDA 21 CFR Part 11, GAMP 5 compliant platform that provides visibility, real time alerts, and reporting on the cryogenic environment in which commodities are stored. The CryoBeacon is a long-range Bluetooth Low Energy (BLE) 5.0 device that logs internal temperatures as low as -200degC, along with ambient temperature and humidity. Users can instantly retrieve data by scanning a QR code, making it easy to monitor both shipments and stationary storage equipment. The MVE SmartTag is a real-time condition-monitoring device with Long Term Evolution (LTE) connectivity and up to 120 days of battery life. It provides continuous visibility and alerts during transport or storage.
お知らせ • Aug 13Cryoport, Inc. announced delayed 10-Q filingOn 08/12/2025, Cryoport, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. For the period, the company is reiterating its revenue guidance for fiscal year 2025: total revenue from continuing operations is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of the control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
お知らせ • Jul 22Cryoport, Inc. to Report Q2, 2025 Results on Aug 05, 2025Cryoport, Inc. announced that they will report Q2, 2025 results at 4:05 PM, US Eastern Standard Time on Aug 05, 2025
お知らせ • Jul 08Cryoport's Mve Biological Solutions Introduces Next Generation Vapor ShippersCryoport, Inc. announced the launch of MVE Biological Solutions' new vapor shippers, the SC 4/2V and SC 4/3V, offering medical and animal health professionals, laboratories, researchers, hospitals and clinics, pharmaceutical companies, and others dramatically improved safety and reliability for transporting and preserving sensitive biological materials at cryogenic temperatures. Built on MVE's legacy SC 4/2V and 4/3V vapor shipper platform, the next-generation SC 4/2V and4/3V models have been redesigned utilizing innovative technologies to offer customers added protection during extended or challenging shipments. These four-liter vapor shippers are engineered to safely transport critical biological materials such as cells and tissues materials for cell therapies, biopharma, reproductive health materials, and animal health materials, including vaccines, while maintaining the materials' integrity throughout the journey. The new SC 4/2V andSC 4/3V vapor shippers include several key advancements designed to enhance performance and reliability. Hold times for both next-generation models have been significantly extended to up to 19 days for the SC 4/2V (previously 13 days) and 26 days for the SC 4/3V (up from 21 days) which provides greater flexibility and security during transit delays. MVE's patented BEND DON'T BREAK™? technology features a specially designed top that flexes under stress, absorbing impact to reduce the risk of damage during rough handling that sometimes happens during shipping. Other upgraded features of the new vapor shippers include a newly integrated lid locking tab which helps prevent breakage, along with MVE's patent-pending Vapor Shield Technology, which minimizes the risk of vacuum loss caused by liquid nitrogen overfilling. These enhancements work together to provide greater reliability and " peace of mind" when transporting critical biological materials.
お知らせ • May 08Cryoport, Inc. Reiterates Revenue Guidance for Full Year Fiscal 2025Cryoport, Inc. reiterated revenue guidance for full year fiscal 2025. The company is reiterating its revenue guidance for fiscal year 2025: total organic revenue is expected to be in the range of $165.0 million to $172.0 million, representing 5% to 10% growth year-over-year. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
お知らせ • Apr 28Cryoport, Inc., Annual General Meeting, Jun 06, 2025Cryoport, Inc., Annual General Meeting, Jun 06, 2025.
お知らせ • Apr 24Cryoport, Inc. to Report Q1, 2025 Results on May 07, 2025Cryoport, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
お知らせ • Apr 02DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX).DHL Supply Chain International Holding B.V. entered into a Sale and Purchase Agreement to acquire Pdp Courier Services (Usa) Inc from Cryoport, Inc. (NasdaqCM:CYRX) on March 31, 2025. In a related party transaction DHL Supply Chain International Holding B.V. also agreed to acquire Courier Polar Expres S.L., Advanced Therapy Logistics and Solutions, SAS and Cryo Express GmbH. for approximately $138 million in cash. The Transaction is expected to close in the second or third quarter of 2025 and is subject to customary closing conditions, including regulatory approval under relevant government antitrust and foreign direct investment laws.
お知らせ • Mar 12Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series with Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical LaboratoriesCryoport, Inc. announced the launch of MVE Biological Solutions' High-Efficiency 800 C, the latest addition to its next-generation High-Efficiency ("HE") Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories. Building on the trusted reputation of the HE Series, the HE 800 C provides ultra-low temperature storage at -190degC, ensuring the integrity of sensitive biological materials. The HE 800 C is compatible with SUC-1 inventory management systems, which enables easy identification and retrieval of samples to streamline sample organization and retrieval. Its superior ergonomic design makes loading and retrieving samples more accessible, reducing strain on laboratory personnel.
お知らせ • Mar 05Cryoport, Inc. Provides Revenue Guidance for the Year 2025Cryoport, Inc. provided revenue guidance for the year 2025. For the year, the company expects revenue guidance in the range of $240 million - $250 million. The Company's 2025 guidance is dependent on its current business and expectations, which may be further impacted by, among other things, factors that are outside of control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.
お知らせ • Feb 18Cryoport, Inc. to Report Q4, 2024 Results on Mar 04, 2025Cryoport, Inc. announced that they will report Q4, 2024 results at 4:05 PM, US Eastern Standard Time on Mar 04, 2025
お知らせ • Jan 22Cryoport, Inc. Unveils Cryoport Express Cryogenic HV3 Shipping SystemCryoport, Inc. unveiled its Cryoport Express Cryogenic HV3 Shipping System ("HV3"), the Company's newest product innovation in Cryoport's comprehensive portfolio of global end-to-end temperature-controlled supply chain offerings. The HV3 ensures unparalleled protection and accessibility for biologics and other temperature-sensitive materials. Its unique rectilinear design eliminates the need for palletization (securing goods on a pallet for transportation) and provides the ability to transport critical life science materials on narrow-bodied aircraft, ensuring compliance with regional carriers and reducing flight rejections and delays. As a result, the HV3 increases the number of available shipping lanes, which will improve patient access and enable life-saving therapies to reach patients in underserved areas. This newly developed shipping system offers enhanced payload protection and resilience during transport. With additional space for non-temperature sensitive accessories and documentation, the HV3 also improves storage efficiency through the ability to stack and nest the shippers, making it more cost-effective and user-friendly. Full compliance with airline requirements plus an integrated condition and location monitoring system provides full Chain of Compliance. Engineered to meet the specific needs of advanced therapies, the HV3 ensures enhanced payload security and superior temperature control, maintaining payload integrity and extended temperature stability at -150degC or lower. The HV3's structure also enhances mobility with its robust wheels and an integrated front-facing handle, improving accessibility at point-of-care sites. Its design also provides for scalability or higher density storage capabilities at manufacturing and clinical sites. While improving overall safety for clinicians and operators, these improvements enable more efficient handling (and storage) at point-of-care site, contract development and manufacturing organizations (CDMO's), and other storage locations, reducing the need for additional site-based resources. The HV3 is also designed to be used with Cryoport's Safepak System. The Safepak System is a purpose built solution that utilizes non-metallic, soft materials to minimize the effects of vibration and shock during the transport of cell and gene therapies.
Reported Earnings • Nov 09Third quarter 2024 earnings released: EPS: US$0.057 (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.057 (up from US$0.31 loss in 3Q 2023). Revenue: US$56.7m (flat on 3Q 2023). Net income: US$2.81m (up US$18.1m from 3Q 2023). Profit margin: 5.0% (up from net loss in 3Q 2023). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$1.62 loss per share (vs US$0.42 loss in 2Q 2023)Second quarter 2024 results: US$1.62 loss per share (further deteriorated from US$0.42 loss in 2Q 2023). Revenue: US$57.6m (up 1.0% from 2Q 2023). Net loss: US$80.0m (loss widened 293% from 2Q 2023). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Aug 07+ 1 more updateCryoport, Inc. (NasdaqCM:CYRX) announces an Equity Buyback for $200 million worth of its shares.Cryoport, Inc. (NasdaqCM:CYRX) announces an share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The repurchase program is valid till December 31, 2027.
お知らせ • Jul 23Cryoport, Inc. to Report Q2, 2024 Results on Aug 06, 2024Cryoport, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
Recent Insider Transactions • May 17Independent Lead Director recently sold €100k worth of stockOn the 15th of May, Richard Jay Berman sold around 8k shares on-market at roughly €12.34 per share. This transaction amounted to 7.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €271k more than they bought in the last 12 months.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.16 loss in 1Q 2023)First quarter 2024 results: US$0.34 loss per share (further deteriorated from US$0.16 loss in 1Q 2023). Revenue: US$54.6m (down 13% from 1Q 2023). Net loss: US$16.9m (loss widened 123% from 1Q 2023). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 08Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024Cryoport, Inc. reiterated revenue guidance for the full year 2024. The Company is reiterating its full year 2024 revenue guidance of $242 million to $252 million and continues to expect revenue to improve progressively throughout the year.
New Risk • May 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$48m net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (7.9% increase in shares outstanding).
お知らせ • May 01Cryoport, Inc. to Report Q1, 2024 Results on May 07, 2024Cryoport, Inc. announced that they will report Q1, 2024 results at 4:05 PM, US Eastern Standard Time on May 07, 2024
お知らせ • Apr 04Cryoport, Inc., Annual General Meeting, May 17, 2024Cryoport, Inc., Annual General Meeting, May 17, 2024, at 10:00 Central Daylight. Agenda: To elect seven directors; to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the company and its subsidiaries for the year ending December 31, 2024; to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in proxy statement for the Annual Meeting; to approve an amendment to the Cryoport, Inc. 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares under the plan; and to transact such other business as may properly come before the meeting or any adjournment thereof.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 7 highly experienced directors. Independent Director Linda Baddour was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 14Cryoport, Inc. Announces Goodwill Impairment for the Quarter Ended December 31, 2023Cryoport, Inc. announced goodwill impairment for the quarter ended December 31, 2023. For the quarter, the company reported Goodwill impairment of $49,569,000.
お知らせ • Mar 13Cryoport, Inc. Provides Revenue Guidance for the Year 2024Cryoport, Inc. provided revenue guidance for the year 2024. The Company is expecting revenue to grow progressively and is providing full year 2024 revenue guidance of $242 million- $252 million.
Reported Earnings • Mar 13Full year 2023 earnings released: US$2.21 loss per share (vs US$0.93 loss in FY 2022)Full year 2023 results: US$2.21 loss per share (further deteriorated from US$0.93 loss in FY 2022). Revenue: US$233.3m (down 1.7% from FY 2022). Net loss: US$107.6m (loss widened 137% from FY 2022). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 28Cryoport, Inc. to Report Q4, 2023 Results on Mar 12, 2024Cryoport, Inc. announced that they will report Q4, 2023 results After-Market on Mar 12, 2024
お知らせ • Feb 16Cryoport, Inc. Announces Transition of Edward Zecchini from the Board of Directors to Sr. Vice President - Chief Digital & Technology OfficerOn February 10, 2024, Edward Zecchini accepted the offer to join Cryoport, Inc. as Senior Vice President – Chief Digital & Technology Officer and submitted his resignation from the Board of Directors of the Company both effective February 19, 2024. There were no disagreements between Mr. Zecchini and the Company on any matter relating to the Company’s operations, policies or practices that led to his decision to resign.
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$47m net loss in 2 years).
お知らせ • Nov 17Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC.Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC on November 16, 2023. Bluebird Express team of seasoned veterans will merge into CRYOPDP's global network and will expand U.S. presence.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Bluebird Express LLC on November 16, 2023.
お知らせ • Nov 10Cryoport, Inc. Provides Revenue Guidance for the Year 2023Cryoport, Inc. provided revenue guidance for the year 2023. The company expects full year 2023 revenue guidance range of $233 million to $243 million.
Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.15 loss in 3Q 2022)Third quarter 2023 results: US$0.31 loss per share (further deteriorated from US$0.15 loss in 3Q 2022). Revenue: US$56.2m (down 7.1% from 3Q 2022). Net loss: US$15.3m (loss widened 109% from 3Q 2022). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 03Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH.Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH on November 2, 2023.Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Tec4Med Lifescience GmbH on November 2, 2023.
お知らせ • Oct 26Cryoport, Inc. to Report Q3, 2023 Results on Nov 08, 2023Cryoport, Inc. announced that they will report Q3, 2023 results at 4:05 PM, US Eastern Standard Time on Nov 08, 2023
Reported Earnings • Aug 10Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.23 loss in 2Q 2022)Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.23 loss in 2Q 2022). Revenue: US$57.0m (down 11% from 2Q 2022). Net loss: US$20.4m (loss widened 82% from 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Aug 03Cryoport, Inc. to Report Q2, 2023 Results on Aug 09, 2023Cryoport, Inc. announced that they will report Q2, 2023 results at 4:05 PM, US Eastern Standard Time on Aug 09, 2023
New Risk • Jul 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years). Significant insider selling over the past 3 months (€142k sold).
お知らせ • Jul 13Cryoport, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023Cryoport, Inc. provided earnings guidance for the second quarter and full year 2023. For the quarter, total revenue is expected to be in the range of $56.5 Million to $57.5 Million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022. For the year, the Company is revising its full year financial outlook, with revenue now expected to be in the range of $233 Million to $243 Million.
Recent Insider Transactions • May 15Independent Lead Director recently sold €142k worth of stockOn the 11th of May, Richard Jay Berman sold around 7k shares on-market at roughly €19.70 per share. This transaction amounted to 6.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €575k more than they bought in the last 12 months.
Reported Earnings • May 05First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.31 loss in 1Q 2022)First quarter 2023 results: US$0.16 loss per share (improved from US$0.31 loss in 1Q 2022). Revenue: US$62.8m (up 20% from 1Q 2022). Net loss: US$7.57m (loss narrowed 51% from 1Q 2022).
お知らせ • May 05Cryoport, Inc. Provides Revenue Guidance for the Year 2023Cryoport, Inc. provided revenue guidance for the year 2023. The company's revenue guidance of $270 million - $290 million for the full year 2023 is expected to be driven largely by ongoing support of global clinical trials, a growing number of commercial cell and gene therapy products from clients, the expansion of cell and gene manufacturing capacity to meet patient demand, and the demand for biostorage and cryogenic freezer systems. The company's 2023 guidance also assumes the launch of new services and products, designed to further expand, and strengthen industry position.
Recent Insider Transactions • Mar 19Chairman recently sold €51k worth of stockOn the 15th of March, Jerrell Shelton sold around 3k shares on-market at roughly €19.73 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jerrell's only on-market trade for the last 12 months.
Breakeven Date Change • Feb 26No longer forecast to breakevenThe 9 analysts covering Cryoport no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.70m in 2025. New consensus forecast suggests the company will make a loss of US$2.40m in 2025.
お知らせ • Feb 16Cryoport, Inc. to Report Q4, 2022 Results on Feb 23, 2023Cryoport, Inc. announced that they will report Q4, 2022 results at 4:05 PM, US Eastern Standard Time on Feb 23, 2023
Breakeven Date Change • Dec 31Forecast to breakeven in 2025The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$7.70m in 2025. Average annual earnings growth of 40% is required to achieve expected profit on schedule.
Recent Insider Transactions • Dec 06Independent Lead Director recently sold €136k worth of stockOn the 1st of December, Richard Jay Berman sold around 7k shares on-market at roughly €18.70 per share. This transaction amounted to 6.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €334k more than they bought in the last 12 months.
Reported Earnings • Nov 05Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.18 loss in 3Q 2021)Third quarter 2022 results: US$0.15 loss per share (improved from US$0.18 loss in 3Q 2021). Revenue: US$60.5m (up 6.7% from 3Q 2021). Net loss: US$7.32m (loss narrowed 14% from 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 04Cryoport, Inc. Revises Revenue Guidance for the Year 2022Cryoport, Inc. revised revenue guidance for the year 2022. The company's revised revenue guidance for the full year 2022 is $232 million - $238 million, and will be driven primarily by the growth from support of global clinical trials and commercially launched therapies from cell and gene therapy clients; growth in temperature-controlled logistics for the life sciences industry; and demand for cryogenic systems solutions.
お知らせ • Oct 28Cryoport, Inc. to Report Q3, 2022 Results on Nov 03, 2022Cryoport, Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 03, 2022
Recent Insider Transactions • Aug 18Independent Lead Director recently sold €115k worth of stockOn the 16th of August, Richard Jay Berman sold around 3k shares on-market at roughly €42.31 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €198k more than they bought in the last 12 months.
Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.16 loss in 2Q 2021)Second quarter 2022 results: US$0.15 loss per share (up from US$0.16 loss in 2Q 2021). Revenue: US$64.2m (up 14% from 2Q 2021). Net loss: US$7.18m (loss narrowed 2.9% from 2Q 2021). Over the next year, revenue is forecast to grow 21%, compared to a 7.2% growth forecast for the industry in Germany.
お知らせ • Aug 05+ 1 more updateCryoport, Inc. (NasdaqCM:CYRX) acquired Cell Matters Sa.Cryoport, Inc. (NasdaqCM:CYRX) acquired Cell Matters Sa on August 4, 2022. Cryoport, Inc. (NasdaqCM:CYRX) completed the acquisition of Cell Matters Sa on August 4, 2022.
お知らせ • Jul 29Cryoport, Inc. to Report Q2, 2022 Results on Aug 04, 2022Cryoport, Inc. announced that they will report Q2, 2022 results After-Market on Aug 04, 2022
Breakeven Date Change • Jun 13Forecast to breakeven in 2024The 9 analysts covering Cryoport expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 84% per year to 2023. The company is expected to make a profit of US$5.75m in 2024. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
